Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

BenzingaDec 13 13:52 ET

FDA's New Accelerated Approval Guidance to Benefit Rare Disease Drug Development, Analysts Believe | NASDAQ:SRPT

Proactive InvestorsDec 13 11:17 ET

Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?

Yahoo FinanceDec 13 09:55 ET

Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com

BusinesswireDec 11 12:41 ET

Based On Its ROE, Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A High Quality Stock?

Simply Wall StDec 10 05:05 ET

Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?

Yahoo FinanceDec 6 11:31 ET